摘要
目的探讨低剂量阿帕替尼联合口服化疗药治疗晚期难治性乳腺癌的临床疗效及不良反应。方法回顾性分析2015年11月—2018年6月我院收治的晚期难治性乳腺癌患者的临床资料,共12例。这些患者经多线治疗失败后抗肿瘤治疗耐受性差,应用低剂量阿帕替尼联合替吉奥或卡培他滨进行治疗。综合评价患者的疗效、无进展生存期(PFS)以及不良反应情况。结果12例患者中部分缓解(PR)占33.3%(4/12),疾病稳定(SD)占41.7%(5/12),疾病进展(PD)占25.0%(3/12);客观缓解率(ORR)为33.3%,疾病控制率(DCR)为75.0%。12例患者中有5例仍在治疗中,其他7例患者的PFS为(4.1±2.6)个月。12例患者的不良反应手足综合征发生率为75.0%(9/12),高血压发生率为41.7%(5/12),疲乏发生率为50.0%(6/12),食欲不振有2例,骨髓抑制2例,牙龈出血、恶心、蛋白尿各有1例。12例中均未见4级及4级以上不良反应。结论多线治疗失败的晚期难治性乳腺癌患者,使用低剂量阿帕替尼联合替吉奥或卡培他滨治疗后,能够较好地控制疾病,生存获益较好,且不良反应相对较小,患者依从性好。
Objective To evaluate the clinical efficacy and adverse reactions of low -dose apatinib combined with oral chemotherapy in the treatment of advanced refractory breast cancer.Methods A retrospective analysis was performed using clinical data from 12 advanced refractory breast cancer patients who were admitted in our hospital from November 2015 to June 2018.The patients failed to receive multi-line therapy,with poor anti -tumor tolerance,and were then treated with low-dose aptatinib combined with tegafur or eapeeitabine.Then,the therapeutic efficacy,the progression-free survival (PFS)and adverse reactions were evaluated.Results The partial remission (PR)rate was 33.3% (4/12),the stable disease (SD)rate was 41.7%(5/12),the progressive disease (PD)rate was 25%(3/12);the disease control rate (DCR)was 75%(9/12) and the objective response rate i ORR)was 33.3%.There were 5 patients who were still under treatment,while the PFS of other 7patients was (4.1±2.6)months.For adverse reactions, the incidences of hand-foot syndrome,hypertension and fatigue was 75.0%(9/12),41.7%(5/12),and 50.0% (6/12),respectively.There were 2 cases of loss of appetite,2 cases of bone marrow suppression,and 1case of proteinuria,1case of bleeding of the gums,and 1 case of nausea.Conclusions After failure of long-term multi-line treatment,advanced refractory breast cancer patients can be treated with low doses of apafitini combined with tegafur or capecitabine,with good disease control and survival benefit,less adverse events and good compliance.
作者
王红梅
赵阳
刘文楼
金振兴
韩正祥
WANG Hongmei;ZHAO Yang;LIU Wenlou;JIN Zhenxing;HAN Zhengxiang(Department of Oncology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221002,China)
出处
《徐州医科大学学报》
CAS
2018年第12期781-786,共6页
Journal of Xuzhou Medical University
基金
江苏省“六大人才高峰”项目(WSW-040)
徐州市科技项目(KC15SH083).
